收藏本站万方检测维普检测中文降重英文语法检测 Turnitin UK版 Turnitin 国际版

登录注册

文献互助

发帖

版主：xxs1234, 1127761702, MRQ, 猜才彩蔡, 1764992075, ARomeo

主题分类：

↓ 下拉展示

新窗全部主题最新热门热帖精华更多

0回复

lig 14 小时前

20 A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

ASH
0回复

lig 前天 10:02

20 A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

ASH
0回复

zhanghao 3 天前

10 Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

ASH
1已完成

emmprin233 3 天前

20 Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies

ASH
0回复

zhanghao 3 天前

10 How I treat plasma cell leukemia

ASH
0回复

zhanghao 3 天前

10 A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study

ASH
1已完成

zhanghao 3 天前

10 Dual-antigen–targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape

ASH
0回复

zhanghao 3 天前

10 Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

ASH
0回复

zhanghao 3 天前

10 Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma

ASH
0回复

gz-1216 4 天前

20 Von Willebrand factor deficiency impairs angiogenesis via angiopoietin-2: relevance for gut angiodysplasia

ASH
0回复

lig 4 天前

30 A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

ASH
0回复

lig 4 天前

20 A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

ASH
0回复

lig 4 天前

20 A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models

ASH
0回复

shaner116 6 天前

10 Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

ASH
0回复

rczx1311 7 天前

10 Harnessing neoantigen-specific T cells for precision immunotherapy in hematologic malignancies

ASH
0回复

muzimumu1223 2026-8-7

10 [补充材料]Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function

ASH
0回复

mlyhhh 2026-8-6

30 The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML

ASH
0回复

xiaxiaxia93 2026-7-29

10 Ker-050, a Novel Inhibitor of Tgfβ Superfamily Signaling, Induces Red Blood Cell Production By Promoting Multiple Stages of Erythroid Differentiation

ASH
0回复

噶噶噶 2026-7-29

10 Patient's T Cell Functionality Determines Blinatumomab-Mediated Killing of B-ALL Leukemia Cells

ASH
0回复

sz2 2026-7-27

50 The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials

ASH

12 3 4 5 6 7 8 9 10 ... 23 / 23 页下一页

悬赏问答

30 Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group

最新回复

站点公告

今日热心研友

（热心研友QQ群）

Powered by 谷粉学术社区X3.4 Copyright © 2001-2025.

湘ICP备2021017706号

深度AI学术|深度AI学术搜索|AI科研狗|小黑屋|版权归属及声明|